#USA #Radnor #financial results #Avantor #VWR Brand

Avantor® Reports Fourth Quarter and Full Year 2025 Results

Avantor, Inc., a significant player in mission-critical products and services for the life sciences and technology sectors, has announced its financial performance for the fourth quarter and full year ending December 31, 2025. This news comes alongside the company's initiation of a Revival program aimed at revitalizing their brand, specifically the relaunch of their VWR brand, enhancing manufacturing and supply chain operations, and improving their e-commerce capabilities.

Fourth Quarter Highlights

In the last quarter of 2025, Avantor's net sales reached $1.66 billion, indicating a minor decline of 1% year-over-year, with a 4% decrease in organic sales. The company reported a net income of $52 million, down significantly from $500 million in Q4 2024, with an adjusted EBITDA of $252 million and a margin of 15.2%. Additionally, the diluted GAAP EPS stood at $0.08, while the adjusted EPS was at $0.22. The operating cash flow was positive at $153 million, contributing to a free cash flow of $117 million.

Annual Performance Overview

The full year results followed a similar trend, with total net sales recorded at $6.55 billion, a drop of 3% compared to 2024. Avantor's net loss for the year was $530 million, a stark contrast to the net income of $712 million for the previous year. The adjusted EBITDA for the full year was $1.07 billion, showcasing the company's efforts to manage operational costs amid the challenges. The diluted GAAP loss per share was reported at $0.78, compared to an earnings of $1.04 per share in 2024.

Strategic Initiatives: The Revival Program

Avantor's CEO, Emmanuel Ligner, emphasized the importance of the Revival program, designed to instill agility and customer-centricity within the organization. This strategic approach includes not only the relaunch of the VWR brand but also critical upgrades across operational processes. The aim is to enhance efficiency and better align offerings with customer needs, demonstrating Avantor's commitment to adapting to market dynamics and revitalizing its competitive positioning.

Ligner stated, "We are moving with urgency to execute the Revival and turn around the performance of this great business. 2026 will be a year of transition and purposeful investment. Our priority is driving top line growth by competing vigorously in the marketplace and strengthening our company."

Segment Analysis

Breaking down performance by segment, Avantor’s Laboratory Solutions segment achieved net sales of $1.11 billion, with a reported decrease of 0.9%, while the Bioscience Production segment reported $548 million, down 2.4%. These results illustrate the challenges faced in maintaining sales momentum across diversified offerings amidst a difficult economic backdrop.

Looking Ahead

The company has communicated its plans for a focused 2026, emphasizing strategic investments that focus on growth and sustainability. The management expressed confidence that their current trajectory will set a strong foundation for future shareholder value creation and operational success.

In conclusion, Avantor remains committed to its strategic priorities, confronting these financial results with a resolve to turn performance around through diligent efforts on operational improvements and an unwavering focus on innovation. Investors and stakeholders can anticipate further announcements as Avantor solidifies its direction moving into the next fiscal year.

For those interested, Avantor will be holding a conference call on February 11, 2026, at 8:00 AM Eastern Time to discuss these results in further detail. This will also be available for replay on the company’s investor relations website. Together, these efforts manifest Avantor's vision of enhancing its role within the life sciences and technology sectors globally.